Literature DB >> 33489928

A Novel Triple-Fluorescent HCMV Strain Reveals Gene Expression Dynamics and Anti-Herpesviral Drug Mechanisms.

Ulfert Rand1, Tobias Kubsch1, Bahram Kasmapour1,2, Luka Cicin-Sain1,2,3,4.   

Abstract

Human Cytomegalovirus (HCMV) infection may result in severe outcomes in immunocompromised individuals such as AIDS patients, transplant recipients, and neonates. To date, no vaccines are available and there are only few drugs for anti-HCMV therapy. Adverse effects and the continuous emergence of drug-resistance strains require the identification of new drug candidates in the near future. Identification and characterization of such compounds and biological factors requires sensitive and reliable detection techniques of HCMV infection, gene expression and spread. In this work, we present and validate a novel concept for multi-reporter herpesviruses, identified through iterative testing of minimally invasive mutations. We integrated up to three fluorescence reporter genes into replication-competent HCMV strains, generating reporter HCMVs that allow the visualization of replication cycle stages of HCMV, namely the immediate early (IE), early (E), and late (L) phase. Fluorescent proteins with clearly distinguishable emission spectra were linked by 2A peptides to essential viral genes, allowing bicistronic expression of the viral and the fluorescent protein without major effects on viral fitness. By using this triple color reporter HCMV, we monitored gene expression dynamics of the IE, E, and L genes by measuring the fluorescent signal of the viral gene-associated fluorophores within infected cell populations and at high temporal resolution. We demonstrate distinct inhibitory profiles of foscarnet, fomivirsen, phosphonoacetic acid, ganciclovir, and letermovir reflecting their mode-of-action. In conclusion, our data argues that this experimental approach allows the identification and characterization of new drug candidates in a single step.
Copyright © 2021 Rand, Kubsch, Kasmapour and Cicin-Sain.

Entities:  

Keywords:  Human Cytomegalovirus; antivirals; herpesvirus; in vitro drug testing; letermovir; live-cell imaging; reporter assay; screening

Year:  2021        PMID: 33489928      PMCID: PMC7820782          DOI: 10.3389/fcimb.2020.536150

Source DB:  PubMed          Journal:  Front Cell Infect Microbiol        ISSN: 2235-2988            Impact factor:   5.293


  37 in total

1.  Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922).

Authors:  G B Mulamba; A Hu; R F Azad; K P Anderson; D M Coen
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides.

Authors:  M F Stinski
Journal:  J Virol       Date:  1978-06       Impact factor: 5.103

3.  En passant mutagenesis: a two step markerless red recombination system.

Authors:  B Karsten Tischer; Gregory A Smith; Nikolaus Osterrieder
Journal:  Methods Mol Biol       Date:  2010

4.  Enhancement of infectivity of murine cytomegalovirus in vitro by centrifugal inoculation.

Authors:  J E Osborn; D L Walker
Journal:  J Virol       Date:  1968-09       Impact factor: 5.103

5.  Myeloid Dendritic Cells Repress Human Cytomegalovirus Gene Expression and Spread by Releasing Interferon-Unrelated Soluble Antiviral Factors.

Authors:  Bahram Kasmapour; Tobias Kubsch; Ulfert Rand; Britta Eiz-Vesper; Martin Messerle; Florian W R Vondran; Bettina Wiegmann; Axel Haverich; Luka Cicin-Sain
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

6.  Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication.

Authors:  Richard J Stanton; Katarina Baluchova; Derrick J Dargan; Charles Cunningham; Orla Sheehy; Sepehr Seirafian; Brian P McSharry; M Lynne Neale; James A Davies; Peter Tomasec; Andrew J Davison; Gavin W G Wilkinson
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

7.  High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice.

Authors:  Jin Hee Kim; Sang-Rok Lee; Li-Hua Li; Hye-Jeong Park; Jeong-Hoh Park; Kwang Youl Lee; Myeong-Kyu Kim; Boo Ahn Shin; Seok-Yong Choi
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

8.  Quantitative temporal viromics: an approach to investigate host-pathogen interaction.

Authors:  Michael P Weekes; Peter Tomasec; Edward L Huttlin; Ceri A Fielding; David Nusinow; Richard J Stanton; Eddie C Y Wang; Rebecca Aicheler; Isa Murrell; Gavin W G Wilkinson; Paul J Lehner; Steven P Gygi
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

9.  Identification of Host Factors Involved in Human Cytomegalovirus Replication, Assembly, and Egress Using a Two-Step Small Interfering RNA Screen.

Authors:  Dominique McCormick; Yao-Tang Lin; Finn Grey
Journal:  mBio       Date:  2018-06-26       Impact factor: 7.867

10.  Real-time transcriptional profiling of cellular and viral gene expression during lytic cytomegalovirus infection.

Authors:  Lisa Marcinowski; Michael Lidschreiber; Lukas Windhager; Martina Rieder; Jens B Bosse; Bernd Rädle; Thomas Bonfert; Ildiko Györy; Miranda de Graaf; Olivia Prazeres da Costa; Philip Rosenstiel; Caroline C Friedel; Ralf Zimmer; Zsolt Ruzsics; Lars Dölken
Journal:  PLoS Pathog       Date:  2012-09-06       Impact factor: 6.823

View more
  2 in total

1.  Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles for Effective Antiviral Therapy.

Authors:  Mikhail Khorenko; Ulfert Rand; Luka Cicin-Sain; Claus Feldmann
Journal:  ACS Biomater Sci Eng       Date:  2022-03-28

2.  Computational modeling of protracted HCMV replication using genome substrates and protein temporal profiles.

Authors:  Christopher E Monti; Rebekah L Mokry; Megan L Schumacher; Ranjan K Dash; Scott S Terhune
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-22       Impact factor: 12.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.